TrialBlood cancer journal2018

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.

Caner Saygin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.